Introduction {#s1}
============

Post-transcriptional regulation is a rapid and efficient way to modulate gene expression used by all organisms. In bacteria, this regulation can involve *cis*-acting regulatory elements such as riboswitches, which bind small molecules and modify transcription elongation, translation or mRNA stability. It can equally involve *trans*-acting factors such as proteins (RNases or RNA binding proteins) and small regulatory RNAs (sRNAs). sRNAs can be encoded in cis (antisense RNA) or in trans relative to their target mRNAs and these regulatory mechanisms can be superimposed on each other to create complex control networks.

The two best-studied model bacteria *Escherichia coli* and *Bacillus subtilis* have evolved with different arsenals of ribonucleases and alternative approaches to the fundamental cellular processes of RNA maturation and degradation ([@bib4]; [@bib14]; [@bib8]). Only eight of the \>30 ribonucleases currently identified in these two bacteria are present in both organisms. *E. coli* depends primarily on endonucleolytic cleavage by RNase E to initiate RNA turnover, followed by degradation of the resulting fragments in a 3'-to-5' orientation by exoribonucleases. *B. subtilis,* on the other hand, has replaced RNase E by an enzyme with similar properties called RNase Y and has the additional option of exonucleolytically degrading RNAs from the 5' end using an enzyme called RNase J1 ([@bib32]). In this regard, *B. subtilis* shares features with the eukaryotic model of RNA decay and this observation has obscured some of the traditional divisions between « prokaryotic » and « eukaryotic » pathways of RNA degradation.

Small regulatory RNAs have been mostly studied in Gram-negative bacteria, especially in *E. coli* and its pathogenic relatives. In these organisms, sRNAs generally act by an imperfect base pairing with their target mRNAs. The interaction between sRNA and mRNA often requires the chaperone Hfq, an Sm-like protein that both stabilizes the sRNA and facilitates the pairing with mRNA targets (for review, see [@bib49]). The sRNA-mRNA interaction can lead to a positive or a negative effect on gene expression. In bacteria, most sRNAs examined to date directly affect mRNA translation with an indirect effect on mRNA half-life (reviewed in [@bib50]). However, some more recent studies have shown that sRNAs are also able to directly affect mRNA stability without affecting translation, by recruiting the degradation machinery or interfering with its action (reviewed in [@bib27]). In one particular example, the ternary complex formed between the sRNA (MicC), the mRNA (*ompD*) and Hfq can recruit RNase E to a site within the open reading frame and stimulate its cleavage by presenting the 5' monophosphate of the sRNA to RNase E ([@bib2]). In another, the sRNA RydC increases the stability of the *cfa* mRNA by pairing to the 5'-UTR of this mRNA, far upstream of the ribosome binding site, and hiding a cleavage site from RNase E ([@bib17]).

Small RNAs have also been studied in some Gram-positive pathogenic bacteria such as *Staphylococcus aureus* and *Streptococcus pyogenes,* but in *B. subtilis*, the paradigm of Gram-positive bacteria, only a handful of sRNAs have been characterized to date and the global mechanisms of sRNA regulation have not been fully resolved ([@bib14]). In these bacteria, Hfq is generally not required for sRNA-mRNA pairing ([@bib22]; [@bib43]) although there are some exceptions in specific organisms ([@bib36]; [@bib6]). One key question is to what extent RNases J1 and Y are influenced by sRNA binding to mRNA targets in *B. subtilis*, i.e. can *E. coli* models involving RNase E be transposed to these RNases in its Gram-positive counterpart?

RoxS ([r]{.ul}elated to [ox]{.ul}idative [s]{.ul}tress) is the unique *trans*-acting sRNA, apart from the ubiquitous 6S RNA, that is conserved between *B. subtilis* and the Gram-positive pathogen *S. aureus*. First identified in *S. aureus* where it is named RsaE, it was shown to regulate genes involved in amino acid and peptide transport, cofactor synthesis, lipid metabolism, carbohydrate metabolism and the TCA cycle ([@bib18]). In a previous study, we showed that RoxS transcription is induced during nitric oxide (NO) stress by the two-component system ResDE and regulates the expression of numerous genes linked to oxido-reduction processes in *B. subtilis* ([@bib12]). In searching for additional direct targets of RoxS that may not have been expressed under the experimental conditions of the first study, we found that RoxS potentially interacts with the extreme 5'-end of the *yflS* mRNA, encoding a malate transporter in *B. subtilis*. We show here that RoxS expression is greatly increased in the presence of malate in the medium and acts as a positive regulator of transporter expression by directly blocking *yflS* mRNA degradation by the 5'−3' exoribonuclease J1. This is the first known case of an sRNA controlling 5\'-exoribonuclease activity in bacteria. RoxS can further stimulate translation of the stabilized *yflS* mRNA, possibly by opening a specific fold of the mRNA that partially occludes the ribosome binding site, providing an additional layer of complexity to the control mechanism. Lastly, we show that RoxS expression is controlled by Rex, a transcriptional repressor of genes linked to fermentation processes that senses the NAD^+^/NADH balance in the cell. The increase in RoxS expression in the presence of malate is explained by a release from Rex-mediated repression, allowing a far more efficient regulation of RoxS targets than seen previously.

Results {#s2}
=======

In a previous study we showed that RoxS, either directly or indirectly, negatively regulates the expression of up to a hundred genes, including two mRNAs encoding proteins involved in central carbon metabolism: *ppnkB* (encoding an inorganic polyphosphate/ATP-NAD kinase) and *sucCD* (encoding succinate dehydrogenase) ([@bib12]). In both cases, RoxS binds to the Shine-Dalgarno (SD) sequences and inhibits translation initiation. To expand the number of direct RoxS targets, we searched for new potential binding sites for this sRNA (TargetRNA2; [@bib24]) that we might have missed in the first study because of the specific growth conditions used (rich medium at 37°C). One such predicted target, the *yflS* mRNA (encoding one of at least four malate transporters in *B. subtilis*) drew our attention because RoxS was predicted to bind to the extreme 5'-end of the mRNA well upstream of the ribosome binding site ([Figure 1](#fig1){ref-type="fig"}).10.7554/eLife.23602.002Figure 1.Base-pairing between RoxS and *yflS* mRNA predicted by the TargetRNA2 program (<http://cs.wellesley.edu/~btjaden/TargetRNA2/>).The transcriptional start (+1) of the *yflS* mRNA is indicated. This was mapped in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and its conservation is shown in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}. The C-rich regions (CRR) of RoxS are in blue. Mutations CRR1 and CRR3 are indicated by arrows.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.002](10.7554/eLife.23602.002)10.7554/eLife.23602.003Figure 1---figure supplement 1.Mapping of the *yflS* 5'-end by primer extension.Total RNA was extracted at mid-exponential phase (OD~600~ = 0.6) from the WT strain grown in the presence of 0.5% malate and treated (+) or not (−) with Xrn1 to digest 5' monophosphorylated RNA. The sequence is labeled as its reverse complement to facilitate direct read-out. The *yflS* transcriptional start (+1) is indicated on the gel. As a control of the digestion of 5' monophosphorylated RNAs with XrnI, a primer extension assay was performed with an oligonucleotide specific for the *hbs* mRNA. Transcripts from *hbs* promoters (P1 and P3, tri-P) and maturation product (M, mono-P) are indicated on the right of the gel.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.003](10.7554/eLife.23602.003)10.7554/eLife.23602.004Figure 1---figure supplement 2.Conservation of the *yflS* promoter and 5\'-UTR in various *Bacilli*.Alignment of the *yflS* promoter region and 5\'-UTR in *Bacilli* containing a clearly identifiable *yflS* gene through synteny. (*B. subtilis* and related bacteria have several di- and tri-carboxylate transporters homologous to YflS making it difficult to identify this particular transporter with certainty). The −35 and −10 regions are indicated, in addition to the transcription initiation site (+1) identified in *B. subtilis*. Conserved nts are indicated with an asterisk.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.004](10.7554/eLife.23602.004)

Mapping of the 5' extremity of the *yflS* mRNA {#s2-1}
----------------------------------------------

The RoxS sRNA is predicted to base-pair to the extreme 5' end of the *yflS* mRNA transcribed from a putative −10 promoter element located 44 nucleotides (nts) upstream of the translational start codon. To confirm the existence of a 5\' end corresponding to this promoter prediction and confirm it was a primary rather than processed transcript, we performed primer extension assays on total RNA with or without pretreatment with the 5'−3' exoribonuclease Xrn1. This ribonuclease only degrades RNAs with a 5'-monophosphate and leaves 5\'-triphosphorylated primary transcripts intact. As a control, we used the *hbs* mRNA, for which two primary transcripts (P3 and P1) and a ribosome-protected maturation product (M) can be detected in vivo ([@bib10]). Treatment of total RNA by Xrn1 caused the 5\'-monophosphorylated end corresponding to the *hbs* maturation product to disappear as expected. In contrast, the 5\' ends corresponding to the P3/P1 primary transcripts of *hbs* and the predicted primary transcript of *yflS* were resistant to Xrn1 treatment ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The primer extension product obtained with the *yflS*-specific oligonucleotide mapped to two consecutive residues ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) suggesting that the *yflS* mRNA can start at an A or G residue, 5 or 6 nts downstream of the predicted −10 region, and thus has a 38/39 nt 5'-UTR. This promoter and 5\'-UTR is highly conserved among *Bacilli* with a clearly identifiable *yflS* gene ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Since the RoxS sRNA sequence is identical to that of *B. subtilis* in these organisms, the predicted base-pairing with the 5\' end of the *yflS* mRNA is likely to be conserved.

RoxS regulates *yflS* mRNA stability {#s2-2}
------------------------------------

The *yflS* gene encodes a malate transporter whose expression is induced by the two-component system (MalKR), which senses the presence of malate in the medium ([@bib48]). To determine whether RoxS had an effect on *yflS* expression, we compared the half-life of this mRNA in WT and *∆roxS* strains grown in 2xTY containing 0.5% malate ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We detected a single band of approximately 1.5 kb corresponding to the predicted size of the full-length *yflS* mRNA on Northern blots of total RNA isolated at different times after addition of rifampicin to stop new transcription. The half-life of the *yflS* mRNA was 2.5 min in a WT strain but decreased to 0.7 min in the absence of RoxS. Thus, RoxS stabilizes the *yflS* mRNA about 3.6-fold, presumably by protecting it from degradation by cellular RNases.10.7554/eLife.23602.005Figure 2.RoxS protects the full-length *yflS* mRNA from RNase J1 degradation in vivo.A representative Northern blot showing total RNA isolated at times after addition of rifampicin (Rif) to (**A**) WT and ∆*roxS* strains, (**B**) ∆*rnc and* ∆*rnc* ∆*roxS* strains, (**C**) ∆*rny and* ∆*rny* ∆*roxS* strains, (**D**) ∆*rnjA and* ∆*rnjA* ∆*roxS* strains and (**E**) ∆*rppH and* ∆*rppH* ∆*roxS* strains grown in the presence of 0.5% malate. Rifampicin was added at mid-exponential phase (OD~600~ = 0.6). Half-lives calculated from two independent experiments (biological replicates) are given under each autoradiogram. The quantification of the Northern blots is presented in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.005](10.7554/eLife.23602.005)10.7554/eLife.23602.006Figure 2---figure supplement 1.RoxS protects the full-length *yflS* mRNA from RNase J1 degradation in vivo.RNA decay curves showing the log percent RNA remaining versus time after rifampicin addition to (**A**) WT and ∆*roxS* strains, (**B**) ∆*rnc and* ∆*rnc* ∆*roxS* strains, (**C**) ∆*rny and* ∆*rny* ∆*roxS* strains, (**D**) ∆*rnjA and* ∆*rnjA* ∆*roxS* strains and (**E**) ∆*rppH and* ∆*rppH* ∆*roxS* strains, grown in the presence of 0.5% malate. The data shown correspond to the quantification of two independent experiments (biological replicates). See also [Figure 2---figure supplement 1---source data 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.006](10.7554/eLife.23602.006)10.7554/eLife.23602.007Figure 2---figure supplement 1---source data 1.Source data for the quantification of *yflS* mRNA half-life in WT and *Bacillus subti*lis RNase mutant strains (*∆rnc, ∆rnc ∆roxS, ∆rny, ∆rny ∆roxS, ∆rnjA, ∆rnjA ∆roxS, ∆rppH, ∆rppH ∆roxS*).**DOI:** [http://dx.doi.org/10.7554/eLife.23602.007](10.7554/eLife.23602.007)

RoxS blocks degradation of the *yflS* mRNA by RNase J1 {#s2-3}
------------------------------------------------------

To identify which RNase(s) attack the *yflS* mRNA in the absence of RoxS, we measured the half-life of the *yflS* mRNA in strains lacking the three main RNases involved in *B. subtilis* mRNA degradation (RNase III, RNase Y and RNase J1). These experiments were done both in the presence and absence of RoxS ([Figure 2B--D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Deletion of the gene encoding RNase III (*∆rnc*) had no major impact on *yflS* mRNA half-life in either the presence (3.1 min) or absence (0.7 min) of RoxS ([Figure 2B](#fig2){ref-type="fig"} compared to [Figure 2A](#fig2){ref-type="fig"}). In the RNase Y (*∆rny*) mutant strain, the full-length *yflS* mRNA was stabilized about 10-fold compared to WT (25.9 min *vs* 2.5 min half-life) and in the *∆roxS ∆rny* double mutant compared to the *∆roxS* single mutant (9.5 min *vs* 0.7 min). This result shows that RNase Y plays a major role in *yflS* mRNA turnover. However, the *yflS* mRNA is still destabilized about 2.7-fold in the absence of RoxS in the *∆rny* mutant background (25.9 min *vs* 9.5 min half-lives, respectively, in the *∆rny* and *∆roxS ∆rny* strains). This suggests that RoxS does not protect the full-length *yflS* transcript from attack by RNase Y and that the effect of RNase Y on *yflS* turnover is RoxS-independent.

The deletion of *rnjA* gene, encoding the 5'−3' exoribonuclease RNase J1, led to a massive accumulation of stable degradation intermediates, presumably the products of endonucleoytic cleavage by RNase Y. The accumulation of these 3\' fragments was similar in the presence or absence of RoxS, consistent with the observation (above) that RNase Y cleavages were RoxS independent. In the presence of RoxS, the stability of the full-length *yflS* mRNA was slightly higher in the *∆rnjA* strain compared to wild-type strains (4 *vs* 2.5 min half-life, respectively). Remarkably, however, deletion of RoxS no longer destabilized the full-length *yflS* mRNA in the *∆rnjA* background (4 *vs* 3.8 min half-lives in *∆rnjA* and *∆roxS ∆rnjA* strains, respectively). Thus, RoxS protects the full-length *yflS* mRNA from degradation by RNase J1 in vivo.

RNase J1 is known to be inhibited by the tri-phosphate group present on the 5\' end of primary transcripts ([@bib32]). Direct attack of the 5\' end of the primary *yflS* transcript by RNase J1 in 5\' exonucleolytic mode would thus require conversion of the 5\' tri-phosphate to mono-phosphate. To date, the only known enzyme to catalyze this reaction in *B. subtilis* is the RNA pyrophosphohydrolase RppH ([@bib42]), although other as yet unidentified enzymes are thought to have similar activity. BsRppH prefers a guanosine residue in the second position of its RNA substrates ([@bib40]). As the *yflS* mRNA fulfills this requirement (i.e. it starts with AG or GG), we measured the half-life of the *yflS* mRNA in both *∆rppH* and *∆roxS ∆rppH* strains ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In the *∆rppH* strain, the half-life was similar to that measured in the wild-type (2.2 *vs* 2.5 min). The *yflS* half-life was also comparable between the *∆rppH ∆roxS* and the *∆roxS* strains (both 0.7 min). Thus, RppH is not the enzyme responsible for the removal of the 5' tri-phosphate of *yflS* mRNA to give access to RNase J1. This result is consistent with the idea that other RNA pyrophosphohydrolase activities are waiting to be identified in *B. subtilis.*

RoxS protects *yflS* mRNA from in vitro degradation by RNase J1 {#s2-4}
---------------------------------------------------------------

The results described above suggested that RoxS protects the *yflS* full-length mRNA from attack by RNase J1 in vivo. To confirm this observation in vitro, we transcribed a fragment corresponding to the first 94 nucleotides of the *yflS* mRNA using T7 RNA polymerase and submitted this transcript to degradation by RNase J1 in the presence or absence of the RoxS sRNA. The RNA contained a ^32^P-labelled 5\'-monophosphate group to mimic the in vivo situation following RNA pyrophosphohydrolase activity. The *yflS* RNA fragment was attacked by RNase J1 in 5\'-exoribonuclease mode as indicated by the accumulation of free radio-labelled AMP at the bottom of the gel, beginning after only 2 min of incubation with the enzyme ([Figure 3](#fig3){ref-type="fig"}, lanes 2--5). In contrast, almost no AMP was visible when the reaction was performed in the presence of RoxS, showing clearly that the 5\' end of *yflS* is protected from RNase J1 by the sRNA ([Figure 3](#fig3){ref-type="fig"}, lanes 8--11).10.7554/eLife.23602.008Figure 3.RoxS protects the *yflS* mRNA from RNase J1 degradation in vitro.(**A**) In vitro degradation of the 5' end of *yflS* RNA by RNase J1 ± RoxS sRNA or RoxS CRR mutants (see [Figure 1](#fig1){ref-type="fig"}). The *yflS* mRNA was in vitro transcribed, dephosphorylated with CIP and radiolabeled at its 5'-end to obtain a 5' monophosphate extremity. Times after RNase J1 addition are indicated at the top of the gel. Reactions were done at 37°C. The migration positions of the *yflS in vitro* transcript (94 nt) and AMP are indicated. (**B**) Percent release of AMP from *yflS* substrate RNA by RNase J1 ± RoxS sRNA or RoxS CRR mutants as a function of time (minutes). The data shown correspond to the quantification of two independent experiments (technical replicates). See also [Figure 3---source data 1](#SD2-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.008](10.7554/eLife.23602.008)10.7554/eLife.23602.009Figure 3---source data 1.Source data for the quantification of *yflS* degradation by RNase J1 in vitro.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.009](10.7554/eLife.23602.009)

RoxS uses C-rich region 3 (CRR3) to interact with the extreme 5'-end of *yflS* mRNA {#s2-5}
-----------------------------------------------------------------------------------

RoxS has four C-rich regions (CRRs) that can potentially base-pair with G-rich complementary sequences in its targets ([Figure 1](#fig1){ref-type="fig"}). In our previous work, we showed that RoxS mainly uses CRR3 to regulate the expression of the *ppnkB* mRNA ([@bib12]). To determine which CRR was most important for the interaction with *yflS*, we repeated the RNase J1 protection experiment using three different mutants of RoxS: one in CRR1, one in CRR3 and one combining both mutations (CRR1+3) ([Figure 1](#fig1){ref-type="fig"}). The RoxS CRR1 mutant still protected *yflS* against RNase J1 ([Figure 3](#fig3){ref-type="fig"}, lanes 14--17), suggesting that this region of RoxS is not important for the interaction with *yflS*. In contrast, the *yflS* RNA was no longer protected by the CRR3 RoxS mutant ([Figure 3](#fig3){ref-type="fig"}, lanes 20--23) or by the double CRR1+3 mutant ([Figure 3](#fig3){ref-type="fig"}, lanes 26--29). These results suggest that the CRR3 region of RoxS is the key C-rich motif for the initiation of base-pairing and protection of the 5\' end of the *yflS* mRNA.

To confirm this result, we made compensatory mutations in the CRR3 of RoxS (CRR3-2) and at the 5\' end of *yflS* (*yflS^mut5\'^*) ([Figure 4A](#fig4){ref-type="fig"}) and assayed the capability of these variants to protect *yflS* from RNase J1 degradation in vitro. The RoxS CRR3-2 mutant showed significantly weaker protection of the *yflS^WT^* transcript than wild-type RoxS ([Figure 4B,C](#fig4){ref-type="fig"}). Even though the *yflS^mut5\'^* RNA was intrinsically a better substrate for RNase J1 than *yflS^WT^*, wild-type RoxS similarly showed weaker protection of the *yflS^mut5\'^* RNA than the CRR3-2 compensatory mutant ([Figure 4B,C](#fig4){ref-type="fig"}). These experiments strongly support the predicted base-pairing between RoxS CRR3 and the 5\' end of the *yflS* mRNA.10.7554/eLife.23602.010Figure 4.RoxS uses C-rich region 3 (CRR3) to interact with the extreme 5'-end of *yflS* mRNA.(**A**) Base-pairing between *yflS* and RoxS, or *yflS^mut5\'^* and RoxS^CRR3-2^ compensatory mutants (**B**) In vitro degradation of the 5' end of *yflS* and *yflS^mut5\'^* transcripts by RNase J1 ± RoxS or the RoxS^CRR3-2^ mutant. *yflS* and *yflS^mut5\'^* mRNAs were in vitro transcribed, dephosphorylated with CIP and radiolabeled at their 5'-end to obtain a 5' monophosphate extremities. Times after RNase J1 addition are indicated at the top of the gel. Reactions were performed at 15°C to facilitate interaction between *yflS^mut5\'^* and RoxS^CRR3-2^ because the ∆G of the compensatory interaction is predicted to be weaker than the wt (−8.0 vs −13.7 kcal/mol). The migration positions of the *yflS* in vitro transcript (94 nt) and AMP are indicated. (**C**) Percent release of AMP from *yflS* and *yflS^mut5\'^* substrate RNAs by RNase J1 ± RoxS or the RoxS^CRR3-2^ mutant as a function of time (minutes). The data shown correspond to the quantification of three independent experiments (technical replicates). Structure probing of RoxS ± *yflS* is shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. See also [Figure 4---source data 1](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.010](10.7554/eLife.23602.010)10.7554/eLife.23602.011Figure 4---source data 1.Source data for the quantification of *yflS* and *yflS^mut^* degradation by RNase J1 in vitro.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.011](10.7554/eLife.23602.011)10.7554/eLife.23602.012Figure 4---figure supplement 1.RoxS uses C-rich region 3 (CRR3) to interact with the extreme 5'-end of *yflS* mRNA.(**A**) Enzymatic probing of the RoxS sRNA secondary structure in the presence and absence of *yflS*. The 5' end-labeled RoxS sRNA was digested with RNase V1 and RNase T2 and run on an 8% polyacrylamide--urea gel. The enzymatic digestions were performed in the absence (−) or in the presence of increasing concentrations of *yflS* mRNA (50, 100 and 400 nM) for digestion by RNase T2, and 50 and 100 nM for the experiment with RNase V1. Incubation controls (in the absence of RNase) were done in the absence (−) and in the presence (+) of *yflS* (400 nM). The positions of CRR1, 2 and 3 are indicated to the right of the gel. The probing experiment was performed twice (technical replicates). (**B**) Secondary structure of the RoxS sRNA and effect of *yflS* binding. Summary of the cleavage patterns generated by RNase V1 (red arrows) and RNase T2 (green arrows). Increased cleavages upon addition of *yflS* are indicated by asterisks, increased protection by circles.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.012](10.7554/eLife.23602.012)

Lastly, we performed structure probing of RoxS in the presence and absence of *yflS* using the RNase V1 (specific for double stranded RNA) and RNase T2 (preference for unpaired adenines). The cleavage sites were in good agreement with the secondary structure of RoxS, as most of the strong RNase T2 cuts were located in the apical loops, while the RNase V1 cuts were primarily located in the helices ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The addition of *yflS* RNA caused limited changes in reactivity restricted to the region encompassing CRR2 and CRR3. Several RNase V1 cleavages were induced close to CRR3 (at nts 63--65). Concomitantly, several RNase T2 cleavages located between CRR2 and CRR3 decreased under the same conditions. Together, these observations show convincingly that, as for the *ppnKB* mRNA, RoxS primarily uses the CRR3 region to hybridize to *yflS* mRNA.

RoxS also activates translation of the *yflS* mRNA {#s2-6}
--------------------------------------------------

The data presented thus far suggests that RoxS binds to the 5' end of the *yflS* mRNA principally via the CRR3 motif to protect it from degradation by RNase J1. To determine the impact of RoxS binding on the conformation of the *yflS* mRNA and potentially on translation, we also probed the secondary structure of the leader portion of *yflS* alone or bound to RoxS. The probes used in this case were RNase V1, RNase T1 (specific for unpaired guanines) and RNase T2. A summary of the results is presented in [Figure 5](#fig5){ref-type="fig"}. In the absence of RoxS, two equilibrium secondary structure models best explain the enzymatic cleavage patterns detected. In the two proposed models, the SD and the AUG start codon are engaged in weak basepairing interactions, while the four guanines at the extreme 5' end of the *yflS* mRNA are accessible to RNase T1 and are therefore in single-stranded conformation. However, we noticed that adenines 11 to 14 were cleaved poorly by RNase T2 compared to other A-stretches (A50-54, A63-66, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Their three-dimensional conformation may therefore be more complex than shown here. Upon addition of RoxS, we observed a significant decrease in the RNase T1 cleavages in the first 10 nucleotides of the *yflS* leader, while adenines 11 to 14 become more accessible to RNase T2. A similar effect was seen with the RoxS CRR1 mutant. However, no major effect was observed with the CRR3 variants, consistent with the idea that CRR3 is the key mediator of the interaction with the 5' end of the *yflS* mRNA. In the absence of RoxS, we also noticed a strong reverse transcriptase (RT) stop between C34 and U35 of the *yflS* leader. This RT stop is located between the SD and AUG start codon and was suppressed by the binding of the wild-type RoxS or the CRR1 mutant, but not the CRR3 variants. These results strongly support the prediction that RoxS base-pairs with the extreme 5' end of the *yflS* mRNA through CRR3, and suggest that RoxS additionally induces a long-range perturbation of the mRNA structure close to the SD sequence.10.7554/eLife.23602.013Figure 5.Modification of the *yflS* mRNA secondary structure upon RoxS binding.Summary of the cleavage patterns ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) of *yflS* alone (two potential equilibrium structures) or bound to RoxS generated by RNase V1 (red arrows), RNase T1 (blue arrows) and RNase T2 (green arrows). Weaker cleavages are represented by dashed arrows. The strong RT stop observed at position U35 (−5 relative to the AUG) is also indicated (black bar). Residues affected by the RoxS binding are indicated by colored asterisks (circles for inhibition; asteriks for stimulation of cleavage). The sequencing ladder was made by reverse transcribing RNA in the presence of dideoxynucleotides. The data suggests that a structural link exists between the 5' extremity and the downstream hairpin structure that contributes to the weak accessibility of the adenines 11 to 14 towards RNase T2 cleavages.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.013](10.7554/eLife.23602.013)10.7554/eLife.23602.014Figure 5---figure supplement 1.Enzymatic probing of the *yflS* mRNA secondary structure in the presence and absence of RoxS.The 5′-end-labeled *yflS* mRNA fragment (nts + 1 to+94) was digested with RNase T1, RNase T2 and RNase V1 and run on a 10% polyacrylamide--urea gel. The enzymatic digestions were performed in the absence (−) or in the presence of increasing concentrations of RoxS (100 or 250 nM). Incubation controls (in the absence of RNase) were done in the absence (−) and in the presence (+) of RoxS (250 nM). Arrows indicate the nucleotides protected by RoxS from the attack by RNase T1 or T2. The Shine--Dalgarno sequence (SD) and the AUG codon (Met), are indicated to the right of the gel. The probing experiment was performed two times (technical replicates).**DOI:** [http://dx.doi.org/10.7554/eLife.23602.014](10.7554/eLife.23602.014)

Since the SD and the AUG codon are predicted to be poorly accessible and some structural changes close to the SD sequence were detected, we asked whether, in addition to protecting the *yflS* mRNA from degradation by RNase J1, RoxS might also have an impact on the translation of this mRNA. We therefore performed toeprinting experiments on the same 94-nt *yflS* leader fragment used for the RNase J1 in vitro degradation and structure probing assays ([Figure 5](#fig5){ref-type="fig"}). The *yflS* transcript was incubated with the 30S ribosomal subunit and initiator tRNA either with or without pre-incubation with RoxS ([Figure 6](#fig6){ref-type="fig"}). In the absence of RoxS, a characteristic reverse transcriptase stop was observed at position +16 relative to the start codon, showing that the translation initiation complex can be formed without RoxS. Addition of wild-type RoxS or the CRR1 mutant increased the signal at +16 approximately 3-fold, suggesting that RoxS stimulates the formation of the translation initiation complex. Significantly less stimulation was observed with the two CRR3 variants; it is possible that the apparent residual effect of these mutants comes from the extended base-pairing around CRR2 in these in vitro experiments. We also detected the strong RT stop between the SD and AUG start codon and, as previously, this species diminished with increasing concentration of wild type RoxS or CRR1 mutant, but not with the CRR3 mutants. The decrease of this signal between C34 and U35 is thus a signature of RoxS binding.10.7554/eLife.23602.015Figure 6.RoxS stimulates 30S binding to the *yflS* mRNA in vitro.Toeprint analysis of wild-type (WT) and various mutant forms of RoxS bound to 50 nM of the *yflS in vitro* transcript (94 nt). The toeprint formed by the 30S ribosomal subunit is indicated at +16 relative to the first nt of the AUG start codon. An additional RT stop at position U35 (−5 relative to the AUG), observed with RoxS variants containing a mutant CRR3 is also indicated. The Shine and Dalgarno sequence is indicated by SD. Three different quantities of RoxS (250, 500 and 1000 nM) were tested. The average stimulation of the toeprint at +16 by RoxS variants, normalized to the *yflS* mRNA alone, from three experiments (technical replicates) is presented under each lane of the autoradiogram, with standard errors as shown.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.015](10.7554/eLife.23602.015)

To confirm the effect of RoxS binding on *yflS* mRNA expression in vivo, we made a *yflS-lacZ* translational fusion in which the promoter, regulatory sequences and the first 436 amino acids (consisting of 11 out of 12 trans-membrane domains) of YflS were fused in frame to LacZ and inserted at the *amyE* locus of the chromosome. We measured the ß-galactosidase activity of this fusion in the presence and absence of RoxS, at different times after induction with malate ([Figure 7](#fig7){ref-type="fig"}). In both strains, ß-galactosidase activity increased progressively after the addition of malate to the growth medium. After 60 min induction, the specific ß-galactosidase activity was 2-fold higher in a WT background compared to the RoxS mutant strain, showing that RoxS stimulates YflS synthesis in vivo.10.7554/eLife.23602.016Figure 7.RoxS stimulates *yflS* translation in vivo.ß-Galactosidase assays of *yflS--lacZ* translational fusions in wild-type (WT) and *∆roxS* strains. The reporter is under control of the *yflS* promoter and regulatory sequences, and consists of 436 amino acids of *yflS* coding sequence fused to *lacZ*. Malate (0.5%) was added at mid-exponential growth phase to induce the expression of the fusion. The levels of ß-galactosidase activity were assayed between 0 and 60 min after malate addition. The specific activity, in nmoles of ONPG hydrolyzed/mg protein/min, was determined in three independent experiments. Error bars indicate the standard deviation for each point. See also [Figure 7---source data 1](#SD4-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.016](10.7554/eLife.23602.016)10.7554/eLife.23602.017Figure 7---source data 1.Source data for the quantification of ß-galactosidase activity of the *yflS-lacZ* fusion.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.017](10.7554/eLife.23602.017)

RoxS blocks *yflS* degradation independently of translation {#s2-7}
-----------------------------------------------------------

Since RoxS had an impact on both translation and degradation of the *yflS* mRNA (see above), it was conceivable that the primary effect of RoxS is on *yflS* mRNA translation. An increase of ribosome trafficking on the *yflS* mRNA could be sufficient to explain the increase in *yflS* stability as has been demonstrated for numerous *trans*-acting sRNAs in bacteria ([@bib27]). To uncouple the effect of degradation and translation, we mutated both the SD sequence (AGGAGA replaced by CAAAAA) and the fifth codon (AAA to TAA) to introduce a premature stop codon in the chromosomal copy of the *yflS* gene. This non-translated variant is called *yflS^mutTR^*. The half-life of *yflS^mutTR^* RNA was slightly decreased compared to the wild-type strain (1.6 min vs 2.5 min respectively; [Figure 8](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), likely due to the decreased ribosome occupancy of the coding sequence and increased access to RNase Y. However, the *yflS^mutTR^* RNA was still destabilized about 2.3-fold in the absence of RoxS compared to the parental strain (1.6 min vs 0.7 min; [Figure 8](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). These results suggest that the stimulation of translation by RoxS is not a prerequisite for the protection of *yflS* mRNA from RNase J1. In other words, RoxS-mediated stimulation of *yflS* mRNA translation and its protection from RNase J1 are independent phenomena.10.7554/eLife.23602.018Figure 8.RoxS stabilizes a non-translated *yflS* mRNA variant in vivo.A representative Northern blot showing total RNA isolated at times after addition of rifampicin (Rif) to WT and ∆*roxS* strains, and *yflS^mutTR^* and *yflS^mutTR^* ∆*roxS* strains grown in the presence of 0.5% malate. Rifampicin was added at mid-exponential phase (OD~600~ = 0.6). Half-lives calculated from two independent experiments (biological replicates) are given under each autoradiogram. The quantification of the Northern blots is presented in [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.018](10.7554/eLife.23602.018)10.7554/eLife.23602.019Figure 8---figure supplement 1.RoxS stabilizes a non-translated *yflS* mRNA variant in vivo.RNA decay curves showing the log percent RNA remaining versus time after rifampicin addition to WT and ∆*roxS* strains, and *yflS^mutSD^* and *yflS^mutSD^* ∆*roxS* grown in the presence of 0.5% malate. The data shown correspond to the quantification of two independent experiments (biological replicates). See also [Figure 8---figure supplement 1---source data 1](#SD5-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.019](10.7554/eLife.23602.019)10.7554/eLife.23602.020Figure 8---figure supplement 1---source data 1.Source data for the quantification of *yflS^mutTR^* mRNA half-life.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.020](10.7554/eLife.23602.020)

RoxS is transcriptionally repressed by Rex {#s2-8}
------------------------------------------

As mentioned previously, the *yflS* gene encodes a malate transporter whose expression is induced by the two-component system MalKR when malate is present in the environment ([@bib48]). Since RoxS post-transcriptionally regulates *yflS* gene expression, we asked whether carbon sources like glucose and malate had an impact on RoxS expression. To test this, we added 0.2% glucose and/or malate to the medium at mid-exponential phase in 2xTY medium and followed RoxS expression for 1 hr by Northern blot ([Figure 9A](#fig9){ref-type="fig"}). RoxS levels increased for about 30 min after addition of glucose before falling again at the 60 min time point. A similar profile, but of much greater amplitude was seen upon addition of malate to the medium and addition of both carbon sources together (malate + glucose) had a cumulative effect on RoxS levels.10.7554/eLife.23602.021Figure 9.Derepression of RoxS expression in strains lacking Rex.(**A**) Northern blot of total RNA extracted from *B. subtilis* W168 (wild-type) before (time 0) and 5, 10, 20, 30 and 60 min after addition of 0.2% malate, 0.2% glucose, or both. (**B**) Northern blot of total RNA extracted from wild-type and *∆resDE* strains before (time 0) and 5, 10, 20, 30 and 60 min after addition of 0.5% malate. (**C**) Same legend as panel B using wild-type and *∆malK* strains. (**D**) Same legend as panel B using wild-type and *∆rex* strains. Quantifications of the Northern blots are from two independent experiments (biological replicates). MalR binding assays are shown in [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}. Conservation of the Rex binding site in different *Staphylococci* and *Bacilli* RoxS promoters is presented [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}. See also [Figure 9---source data 1](#SD6-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.021](10.7554/eLife.23602.021)10.7554/eLife.23602.022Figure 9---source data 1.Source data for the quantification of RoxS derepression by malate in *Bacillus subtilis* mutant strains (*∆resDE, ∆malK, ∆re*x).**DOI:** [http://dx.doi.org/10.7554/eLife.23602.022](10.7554/eLife.23602.022)10.7554/eLife.23602.023Figure 9---figure supplement 1.MalR does not bind the RoxS promoter.EMSA of ^32^P-labelled double-stranded DNA fragments (0.5 pmol) containing the *maeA* MalR operator, the RoxS promoter or an internal portion of the *yflS* coding sequence. The amounts of MalR in the binding reaction are indicated (in pmoles) above each lane. EMSAs were performed twice (technical replicates).**DOI:** [http://dx.doi.org/10.7554/eLife.23602.023](10.7554/eLife.23602.023)10.7554/eLife.23602.024Figure 9---figure supplement 2.Alignment of RsaE/RoxS sequences from different *Staphylococci* and *Bacilli* adapted from [@bib12].The RoxS sequences are boxed in blue. Likely −35 and extended −10 sequences are boxed in mauve and the ResD and Rex binding sites are boxed in green and pink, respectively. The consensus binding sequences for *B. subtilis* and *S. aureus* Rex are indicated ([@bib23]; [@bib39]). Positions showing 100% conservation are indicated by asterisks. Abbreviations are as follows: Sepi, *S. epidermis*; SauCol, *S. aureus* Colindale strain; Shae, *S. haemophilus*; Ban, *B. anthracis*; SauNew, *S. aureus* Newman strain; Bli, *B. lichiniformis*; Bpu, *B. pumilus*; Bsub, *B. subtilis*.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.024](10.7554/eLife.23602.024)

We performed a number of experiments to determine the regulator of RoxS expression in the presence of malate from among three potential candidates ResDE, MalKR and Rex. We had previously shown that RoxS is induced by nitric-oxide (NO) in the growth medium *via* the two-component system ResDE ([@bib12]). We therefore first tested the involvement of ResDE in the induction of RoxS expression by malate ([Figure 9B](#fig9){ref-type="fig"}). In the *∆resDE* mutant strain, RoxS levels were lower than in the WT strain, as observed previously ([@bib12]). However, RoxS levels were still inducible by malate in the absence of ResDE, with the same kinetics as in the WT strain, showing that ResDE is not involved in this regulation.

The two-component system MalKR, known to respond to malate levels in *B. subtilis* and responsible for induction of *yflS* expression (see above), was also a good candidate for RoxS regulation by malate. In a *∆malKR* strain mutant, RoxS levels no longer increased upon addition of malate ([Figure 9C](#fig9){ref-type="fig"}), suggesting a role for this two-component system in regulation. However, a comparison of the RoxS promoter sequence to those of the *maeN*, *maeA* and *yflS* genes, all known to bind MalR, did not reveal any obvious similarities. We purified the MalR protein and performed an electrophoretic mobility shift assay (EMSA) with a DNA fragment corresponding to the RoxS promoter, with the *maeA* promoter as a positive control and a portion of the *yflS* coding region as a negative control ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). We confirmed binding of MalR to the *maeA* promoter but found no specific interaction with the RoxS promoter region. These data suggest that the effect of the MalKR two-component system on RoxS levels is indirect.

Further examination of the sequence around the RoxS transcription start site revealed the presence of a potential binding site for the Rex transcriptional repressor ([@bib23]) immediately downstream of the transcription start site ([Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}). We therefore examined the induction of RoxS expression upon addition of malate to a *∆rex* strain. In the absence of Rex, RoxS levels were already high before addition of malate induction and accumulated to even higher levels over time ([Figure 9D](#fig9){ref-type="fig"}). Furthermore, we no longer observed the reduction in RoxS levels one hour after malate addition. This result suggests that Rex represses RoxS transcription and that addition of malate to the growth medium causes a transient release from this repression for at least 30 mins (see discussion). To demonstrate that Rex directly binds the RoxS promoter region, we performed EMSA experiments with the *roxS* and the lactate dehydrogenase (*ldh*) gene promoter sequences, and with a portion of the *yflS* coding region as a negative control ([Figure 10](#fig10){ref-type="fig"}). As expected, we did not observe complexes with the *yflS* coding region but we detected gel-shifted species with the *ldh* promoter, known to bind Rex ([@bib51]). We also obtained a gel-shifted species for the *roxS* promoter fragment, confirming that Rex can directly bind this promoter region and explaining how it can inhibit transcription. Interestingly, the Rex protein and its predicted binding site just downstream of the *roxS* promoter are conserved in *S. aureus* and in Staphylococcaceae in general ([@bib39]), suggesting similar regulation may occur in these pathogenic bacteria ([Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}).10.7554/eLife.23602.025Figure 10.Rex binds the RoxS promoter region in vitro.Electrophoretic mobility shift assays (EMSA) of ^32^P-labelled double-stranded DNA fragments (0.1 pmol) containing the *ldh* Rex operator, the RoxS promoter or an internal sequence of *yflS* coding sequence. The quantities of Rex in the binding reaction are indicated (in pmoles) above each lane. EMSAs were performed three times (technical replicates).**DOI:** [http://dx.doi.org/10.7554/eLife.23602.025](10.7554/eLife.23602.025)

RoxS regulates *ppnkB* and *sucC* mRNA stability far more efficiently in the presence of malate {#s2-9}
-----------------------------------------------------------------------------------------------

In our previous studies, we showed that RoxS blocks translation of the *ppnkB* and *sucC* mRNAs and indirectly destabilizes these transcripts ([@bib12]). Since RoxS expression is derepressed in the presence of malate, we retested the impact of RoxS on these two mRNAs in these growth conditions. We measured the half-lives of the *ppnKB* and *sucCD* mRNAs in the presence or in absence of malate by Northern blotting of RNAs isolated at different times after rifampicin addition. We previously showed that RoxS destabilized the *ppnkB* about 2-fold and had little impact on *sucCD* mRNA half-life in 2xTY with no added carbon source ([Figure 11A](#fig11){ref-type="fig"} and \[[@bib12]\]). In 2xTY plus malate, however, RoxS destabilized the *ppnkB* mRNA about 20-fold and the *sucD* mRNA about 8-fold ([Figure 11B](#fig11){ref-type="fig"}). This result confirms our previous data and shows that RoxS has a far greater impact on gene expression in the presence of malate.10.7554/eLife.23602.026Figure 11.The effect of RoxS on *ppnKB* and *sucCD* mRNA stability is amplified in the presence of malate.(**A**) Northern blot of total RNA isolated at times after addition of rifampicin (rif) to WT and ∆*roxS* strains. Rifampicin was added at mid-exponential phase (OD~600~ = 0.6). The half-lives of the *ppnkB* and *sucCD* mRNAs are indicated below the blot. (**B**) Same legend as panel A but with 0.5% malate in the medium. Northerns were performed twice (biological replicates).**DOI:** [http://dx.doi.org/10.7554/eLife.23602.026](10.7554/eLife.23602.026)

Discussion {#s3}
==========

In this study, we report for the first time that a small regulatory RNA (RoxS) can directly prevent 5'-to-3' mRNA degradation of its mRNA target. RoxS binds to the 5\' end of the *yflS* mRNA through base-pairing interactions primarily with the C-rich region CRR3 ([Figure 1](#fig1){ref-type="fig"}). The inhibitory effect on RNase J1 5\'−3\' exoribonuclease activity can easily be understood in structural terms; the RNA binding channel that leads to the RNase J1 catalytic site is only long enough to accommodate 4--5 nts of single stranded RNA. The unbound *yflS* mRNA is predicted to have at least six unpaired nts before the first hairpin structure ([Figure 5](#fig5){ref-type="fig"}) and would thus be expected to be a good substrate for RNase J1 once the 5\'-triphosphate group has been removed. When bound to RoxS, the duplexed 5\' end of the *yflS* RNA can no longer reach the catalytic site, explaining how it is protected from degradation.

To our knowledge, there are only three other examples of direct mRNA stabilization by a *trans*-acting regulatory RNA in Gram-positive bacteria. In *Streptococcus mutans*, the 5'-UTR of the intact *irvA* mRNA interacts with the coding sequence of the *gbpC* mRNA, encoding a surface lectin implicated in dextran dependent aggregation stress (DDAG). This interaction blocks endoribonucleolyic cleavage of the *gbpC* mRNA by RNase J2 ([@bib31]). [@bib38], [@bib37]) showed that the *Clostridium perfringens colA* mRNA (encoding collagenase) is stabilized by the VR-RNA. Binding of the sRNA to the *colA* mRNA leads to a cleavage its 5'-UTR, which releases the *colA* SD sequence and stimulates translation initiation. The stabilization of *colA* depends on the binding of a ribosome to the SD sequence, but translation has no impact on mRNA stability. In the pathogen *Streptococcus pyogenes*, the FasX sRNA stabilizes the streptokinase encoding mRNA (*ska*) ([@bib41]) by binding to its extreme 5\' end *via* a sequence resembling that of the RoxS CRR3 (four consecutive C\'s matched with four consecutive G\'s). Our data would suggest that RNase J1 is a prime candidate for FasX regulation of the *ska* mRNA. In fact, the sRNA-dependent 5\' end protection mechanism discovered here could in theory be used to activate expression of any mRNA in any microorganism by shielding it from enzymes (e.g. RppH, RNase J1, RNase E) requiring a single stranded 5' extremity to initiate degradation.

Our data also indicate that binding of RoxS to the 5\' end of the *yflS* mRNA both protects it from degradation by RNase J1 ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) and stimulates 30S binding to the SD sequence in vitro ([Figure 6](#fig6){ref-type="fig"}), suggesting an activation of translation. Moreover, the increased expression of the *yflS(436)-lacZ* fusion in the presence of RoxS is consistent with an increase in translation efficiency ([Figure 7](#fig7){ref-type="fig"}). We were able to uncouple the effect of RoxS on *yflS* mRNA stability and translation by making a non-translated variant (*yflS^mutTR^*) and showed that RoxS is still able to stabilize this mRNA independently of translation ([Figure 8](#fig8){ref-type="fig"}). However, in all likelihood, the two events are indissociable in vivo with the wild-type *yflS* mRNA, that is, stabilization of the mRNA and increased translation go hand in hand to produce more of the YflS transporter in the presence of malate.

The enzymatic probing of *yflS* mRNA indicated that the binding of RoxS, in addition to protecting the 5\' end from RNase T1 cleavage, causes subtle modifications of the secondary structure of the *yflS* leader, that could account for the stimulation of initiation complex formation. Most noticeably, a strong RT stop between C34 and U35 (five nucleotides upstream of the AUG) is lost upon binding of WT RoxS or the CRR1 mutant, but is retained when *yflS* mRNA is incubated with the inactive CRR3 variant. This suggests a structural modification to the apex of the stem-loop in the vicinity of the SD sequence upon binding to RoxS. Surprisingly, however, no other nucleotides in this neighborhood became more reactive to single stranded probes (e.g. RNase T1) in the presence of RoxS, in particular the two G-C pairs (25G/34C and 26G/33C) that are predicted to close the apical loop ([Figure 5](#fig5){ref-type="fig"}). This suggests that the 3D structure of *yflS* leader and the impact of RoxS may be more complex than the model presented in [Figure 5](#fig5){ref-type="fig"}. The *yflS* mRNA sequence contains several stretches of consecutive G-residues in the first 50 nts that could potentially form G-quadruplex RNA structures ([@bib25]). Alternatively, part of the 5' leader including the AAACAA sequence (nts 12--17) of *yflS* mRNA could potentially form a triple helix with the stem of the adjacent hairpin rich in AU pairings. In both cases, RoxS binding would disrupt a tertiary fold favoring the recognition of the ribosome. Our structure probing data are consistent with a model in which the duplex formed by binding of RoxS to the 5' end of the *yflS* mRNA not only blocks RNase J1 access but also disrupts a particular fold of the 5'UTR that is unfavorable to ribosome recruitment.

Our study showed that the expression of the RoxS sRNA is not only induced by nitric oxide (NO) as we described previously ([@bib12]), but also by the presence of malate in the growth medium ([Figure 9](#fig9){ref-type="fig"}). The malate-induced increase in RoxS expression is indirectly dependent on the two-component system MalKR and directly dependent on release from Rex repression ([Figures 9](#fig9){ref-type="fig"} and [10](#fig10){ref-type="fig"}). The Rex repressor is a sensor of the NAD^+^/NADH ratio in the cell. It has a 20,000-fold higher affinity for NADH than for NAD^+^ and the binding of NADH to Rex provokes a structural rearrangement which prevents its binding to target promoters and allows the expression of genes involved in fermentation ([@bib29]; [@bib51]; [@bib33]). The temporary release from Rex-mediated repression of RoxS expression may be linked to the generation of NADH in the early steps of malate metabolism, either in the conversion of malate to oxaloacetate by malate dehydrogenase (Mdh) in the TCA cycle, or its conversion to pyruvate by the malic enzymes MaeA, MalS and MleA ([@bib11]; [@bib30]; [@bib34]) ([Figure 12](#fig12){ref-type="fig"}). The effect of the MalKR mutation on RoxS expression ([Figure 9C](#fig9){ref-type="fig"}) is most likely explained by the decrease in expression of the MalKR regulon, consisting of the malate transporter genes *yflS* and *maeN,* and that of the malic enzyme *maeA,* and the consequent impact on NADH levels and Rex activity.10.7554/eLife.23602.027Figure 12.Model of various roles of RoxS upon addition of malate to culture medium.For details see text. Panel A shows reactions affected by RoxS that impact NAD(P)^+^/NAD(P)H balance. Panel B shows the role of RoxS in *yflS* mRNA degradation. Targets negatively regulated by RoxS are in red; targets positively regulated by RoxS are in green.**DOI:** [http://dx.doi.org/10.7554/eLife.23602.027](10.7554/eLife.23602.027)

*B. subtilis* has at least four malate transporters: MaeN ([@bib52]) and YflS ([@bib48]), both regulated by the two-component system MalKR ([@bib48]), and MleN ([@bib52]) and CimH, the latter of which is primarily a transporter of citrate ([@bib46]). Malate is a common source of carbon for *B. subtilis* in its natural habitat since it is released by the roots of many plants ([@bib44]). Most of the malate imported by *B. subtilis* cells serves in gluconeogenesis and the excess is sent towards overflow metabolism/fermentation and the production of lactate, acetate, acetoin and 2,3-butanediol ([@bib26]) ([Figure 12](#fig12){ref-type="fig"}). This overflow metabolism/fermentation allows NAD^+^ regeneration, primarily catalyzed by lactate dehydrogenase (Ldh/LctE) that converts pyruvate to lactate ([@bib9]) ([Figure 12](#fig12){ref-type="fig"}). Transcription of the *maeN* mRNA, encoding the main malate transporter, is essentially turned off during fermentation and ethanol stress ([@bib35]). It is possible that RoxS specifically stabilizes the *yflS* mRNA to compensate for this decrease in *maeN* expression, thus facilitating the continued uptake of malate during conditions where the fermentation/overflow pathway is turned on.

The identification of Rex as a regulator of RoxS expression significantly expands the Rex regulon and contributes to our understanding of the pivotal role of Rex in Bacilli ([@bib28]); up to now only a handful of fermentation pathway genes or operons were known to be directly repressed by this transcriptional regulator. Our previous study showed that 30% of genes with increased expression in a ∆*roxS* strain are linked to oxido-reduction processes ([@bib12]). Its down-regulated targets include *ppnKB,* encoding NAD-kinase, and the TCA cycle components *sucCD* and *citZ*. PpnKB and the TCA cycle are significant contributors to the production of NADPH and NADH, respectively ([Figure 12](#fig12){ref-type="fig"}). These observations, together with the fact that RoxS is regulated by the NADH-sensitive transcriptional repressor Rex, suggest that a key role of RoxS is to temporarily turn down part of the TCA cycle to help restore the NAD^+^/NADH balance. In the presence of malate, this re-equilibration is further aided by the increased activity of Ldh regenerating NAD^+^ (see above). Once the NAD^+^/NADH ratio is restored, Rex would be predicted to become active again as a repressor, explaining the decrease in RoxS levels seen in Northern blots about one hour after addition of malate and the loss of this down-regulation in the Rex mutant ([Figure 9D](#fig9){ref-type="fig"}). In further agreement with a role for RoxS in managing NADH levels, we showed in our previous report that expression of the lactate dehydrogenase gene (*ldh*) and the *cydA* gene, encoding a subunit of cytochrome bd, is up-regulated in *∆roxS* cells ([@bib12]). Neither of these mRNAs is predicted to be a direct target of RoxS, but both are members of the Rex regulon. Their increased expression is thus most likely indicative of higher intracellular NADH levels and Rex derepression in the *∆roxS* strain. Interestingly, a link between NO levels and regulation of virulence via NADH and Rex has been proposed in *S. aureus* ([@bib39]). The conservation of the Rex binding site downstream of the RsaE/RoxS promoter in *S. aureus* suggests that this pathway is evolutionarily conserved to best serve the adaptation of *B. subtilis* and *S. aureus* to their respective niches.

Materials and methods {#s4}
=====================

Strains and constructs {#s4-1}
----------------------

Strains and oligonucleotides used are provided in [Supplementary files 1](#SD7-data){ref-type="supplementary-material"} and [2](#SD8-data){ref-type="supplementary-material"}, respectively.

Strain CCB803 (*malKR::spc*) was constructed by transforming *B. subtilis* W168 (SSB1002) with a PCR fragment generated by re-amplifying (oligo pair CC1722/CC1716) three overlapping PCR fragments corresponding to upstream (oligo pair CC1715/CC1717), downstream (oligo pair CC1719/CC1721) regions of the *malKR* operon and the spectinomycin resistance cassette (oligo pair CC1718/CC1720) from plasmid pDG1727 ([@bib20]).

Strain CCB952 (*rex:pMUTIN ery*) was constructed by transforming the *B. subtilis* W168 strain with chromosomal DNA from strain MGNA-C201 from the Japanese National Institute of Genetics (NIG) collection.

The *yflS*(436)*-lacZ* fusion was constructed using a PCR fragment generated by amplifying the *yflS* gene (oligo pair CC1734/CC1789) including 436 amino acids of the coding sequence (−81 to +1347 relative to transcription start site) and cloned between the *Eco*RI and *Sal*I restriction sites of the integrative plasmid pHM2 ([@bib19]). *B. subtilis* W168 and CCB485 (*roxS::kan*) strains ([@bib12]) were transformed with pHM2-*yflS*(436)-*lacZ* yielding strains CCB831 and CCB832, respectively.

Strain CCB1022 (*yflS^mutTR^*) was made by markerless mutation of the Shine-Dalgarno sequence and fifth codon of *yflS* using plasmid pMAD-yflS^mutTR^ according to [@bib1]. Plasmid pMAD-yflS^mutTR^ was constructed as follows. Overlapping upstream and downstream fragments containing the mutation in *yflS* SD region (AGGAGA to CAAAAA) in the upstream fragment and the stop codon mutation in the downstream fragment were amplified using oligo pairs CC1656/2050 and CC2047/1657, respectively. The overlapping fragments were then assembled in a new PCR reaction with CC1656/1657, digested with *Sal*I and cloned in pMAD. Strain CCB1027 (*yflS^mutTR^ ∆roxS)* was made by transformation of strain CCB1022 with chromosomal DNA of CCB485 (*roxS::kan)*.

RNA isolation and northern blots {#s4-2}
--------------------------------

RNA was isolated from mid-log phase *B. subtilis* cells growing in 2×YT medium either by the glass beads/phenol method described in [@bib3] or by the RNAsnap method described in [@bib47]. Northern blots were performed as described previously ([@bib13]). The *yflS* riboprobe was transcribed in vitro using T7 RNA polymerase (Promega) and labeled with \[α-^32^P\]-UTP using a PCR fragment amplified with oligo pair CC1566/CC1567 as template.

Mapping of 5' ends by primer extension assays following Xrn1 digestion {#s4-3}
----------------------------------------------------------------------

Primer extension assays were performed as described previously on total RNA ([@bib7]) with the *yflS* oligo (CC1537) and *hbs* oligo (CC463) 5' end-labeled with T4 polynucleotide kinase (PNK) and \[γ-^32^P\]-ATP. Xrn1 depletion of 5' monophosphorylated RNA was performed as described in [@bib45]. Briefly, 15 µg of total RNA was digested for 1 hr at 37°C with 2 units of XrnI in NEB buffer 3. Total treated and non-treated RNAs were phenol extracted and ethanol precipitated. The efficiency of digestion was tested by running total RNA on an agarose gel to visualize digestion of ribosomal RNA.

RNase J1 assays {#s4-4}
---------------

The 94-nt *yflS* and *yflS^mu^*^t*5\'*^ RNA fragments were transcribed in vitro from PCR fragments containing the leader region and the first 55 nts of the *yflS* coding sequence. The *yflS* and *yflS^mu^*^t*5\'*^ templates were amplified with the oligo pairs CC1658/CC1537 and CC1537/CC2040 respectively. RoxS and its mutant derivatives (CRR1, CRR3 and CRR1+3) were made similarly using PCR fragments amplified from their respective plasmids 639, 640 and 641, using oligos CC1832/CC1833 ([@bib12]). The CRR3-2 mutant was made by overlapping PCR. The CCCCU sequence of CRR3 was mutated to UUCUC using oligo pairs CC1832/CC2042 and CC1833/CC2041 and reamplified with CC1832 and CC1833. The *yflS* RNA was dephosphorylated with Calf Intestinal Phosphatase (CIP) (10 U/µl; Biolabs) and 5' end-labeled with T4 polynucleotide kinase (PNK) and \[γ-^32^P\]-ATP. The *yflS* RNA (1.2 pmol), RoxS and its mutant derivatives (3 pmol) were pre-heated separately 5 min at 95°C in water or transcription buffer, respectively, and slowly cooled to 20°C. The *yflS* RNA was mixed with RoxS or its mutant derivatives in 1X J1 buffer (20 mM Tris pH 6.8, 8 mM MgCl2, 100 mM NH4Cl, 0.1 mM DTT). The reaction was incubated at 37°C or at 15°C (as indicated) and stopped with RNA loading dye (Ambion) before (time 0) and 2, 4, 6 and 10 min after addition of RNase J1 (0.5 μg per reaction) at 37°C, and 30 and 60 min after addition of RNase J1 at 15°C. RNA was also incubated without RNase J1 for 10 min at 37°C or 60 min at 15°C as a control.

Toeprinting assays {#s4-5}
------------------

The *yflS* RNA fragments were transcribed in vitro as described for RNase J1 assays. The transcribed RNAs were purified from 8% polyacrylamide-8M urea gels. After elution in 0.5 M ammonium acetate/1 mM EDTA buffer, the RNAs were precipitated twice with ethanol. The 5' end-labeling of dephosphorylated DNA oligonucleotides was performed with T4 PNK and \[γ-^32^P\]-ATP. Before use, RNAs were denatured/renatured by incubation at 90°C for 2 min in the absence of magnesium and salt, then 1 min on ice, followed by an incubation step at 37°C for 15 min in TMN buffer (20 mM Tris-acetate pH 7.5, 10 mM magnesium acetate, 150 mM sodium acetate). Toeprints were performed with *E. coli* 30S subunits. The preparation of ribosomal subunits, the formation of a simplified translational initiation complex with mRNA and the primer extension conditions were performed according to [@bib15]. Standard conditions contained 15--50 nM RNA transcript annealed to a 5' end-labeled oligonucleotide (CC1537: complementary to codons 11 to 18), 250 nM *E. coli* 30S ribosomal subunits, and 40 to 80 nM of RoxS in 10 μl final volume of buffer containing 20 mM Tris-acetate, pH 7.5, 60 mM NH~4~Cl, 10 mM magnesium acetate, and 3 mM ß-mercaptoethanol. After 10 min at 37°C, the initiator tRNA (1 μM) was added and the reaction was incubated for a further 5 min at 37°C. Reverse transcription was performed with one unit of AMV reverse transcriptase for 15 min at 37°C.

Probing of RNA secondary structure {#s4-6}
----------------------------------

Structure probing of RoxS was performed with wild-type RoxS labeled at its 5' end using \[γ-^32^P\]-ATP and T4 polynucleotide kinase (Ambion). Complex formation was performed with 5' end-labeled RoxS and increasing concentrations of cold *yfl*S mRNA (0.5, 1 and 4 pmoles). The two RNAs were denatured at 90°C for 1 min in sterile H~2~O and cooled on ice for 1 min; hybridization was at 20°C for 15 min in 1xTMN buffer (20 mM Tris-HCl pH 7.5, 10 mM MgCl~2~, 150 mM KCl). Enzymatic hydrolysis was performed on 5' end-labeled RoxS (50,000 cps) either alone or bound to *yfl*S mRNA (final concentrations of 50, 100, 400 nM) in the presence of 1 µg carrier tRNA in a total volume of 10 µl containing TMN buffer. Reactions were done at 20°C for 5 min with RNase V1 (0.008 U, Ambion), or for 10 min with RNase T2 (0.025 U, MoBiTech). Hydrolysis was stopped by phenol extraction followed by RNA precipitation. The 5' end-labeled RoxS fragments were migrated on 8% polyacrylamide/8 M urea gels.

Structure probing of *yflS* mRNA was performed with the 94 nts *yflS* transcript (see RNase J1 assays). Complex formation between *yflS* mRNA and increasing concentrations of RoxS sRNA was carried out as follows. Both RNAs were annealed under the same conditions as described just above. The reactions were performed on *yflS* (0.5 pmole) either alone or bound to RoxS in a total reactional volume of 10 µL in TMN Buffer 1X, in the presence of 1 µg carrier tRNA. Enzymatic hydrolysis was performed at 20°C for 5 min with 0.004 U of RNase V1 (Ambion) or 0.5 U of RNase T1 (Thermo Scientific), and at 20°C for 10 min with 0.025 U of RNase T2 (MoBiTech). The reactions were stopped by precipitation of the RNA by adding 20 µL of a solution containing 1M guanidine thiocyanate, 0.167% N-lauryl sarcosine, 10 mM DTT and 83% isopropanol. The enzymatic cleavages were detected by primer extension using an end-labeled oligonucleotide (CC1537) and reverse transcriptase as previously described ([@bib21]). The cleavage sites were analyzed after fractionation of the DNA fragments on a 10% polyacrylamide-8 M urea gel-TBE 1X followed by autoradiography.

Electrophoretic mobility shift assays (EMSA) {#s4-7}
--------------------------------------------

For EMSA assays with Rex, a DNA fragment containing the *ldh* gene Rex operator was prepared by annealing two oligonucleotides LDH2F/LDH2R (a kind gift from C. von Wachenfeldt) ([Supplementary file 1](#SD7-data){ref-type="supplementary-material"}) in binding buffer (100 mM NaCl and 10 mM Tris, pH 8). DNA fragments containing the RoxS promoter and an internal sequence of the *yflS* ORF were synthetized by PCR using the oligo pairs CC1859/CC1860 and CC1578/CC1768, respectively. Oligos were radiolabelled using PNK and \[γ-^32^P\]-ATP. Binding reactions (20 µl) were performed in 10 mM potassium phosphate buffer (pH 7.5), 10% glycerol, 1 µg herring sperm DNA as non-specific competitor, and contained approximately 0.1 pmol of labelled DNA.

For EMSA assays with MalR, a DNA fragment containing the *maeA* MalR operator was synthetized by PCR using the oligo pair CC1861/CC1862. DNA fragments containing the RoxS promoter and an internal sequence of *yflS* ORF were prepared as described above for the EMSA experiment with Rex. Oligos were radiolabelled using PNK and \[γ-^32^P\]-ATP. Binding reactions (20 µl) were performed in 10 mM Tris-HCl buffer (pH 8), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 5% glycerol, 1 µg herring sperm DNA as non-specific competitor, and contained approximately 0.5 pmol of labeled DNA.

All EMSA reactions were incubated for 15 min at 30°C then loaded onto a native 6% polyacrylamide gel in TBE. Gels were run at 4°C at 150 V, dried and analyzed by Phosphor Imager.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"sRNA-mediated activation of gene expression by inhibition of 5\'-3\' exonucleolytic mRNA degradation\" for consideration by *eLife*. Your article has been favorably evaluated by Richard Losick (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal his identity: David Bechhofer (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript by Sylvain Duran et al. reports the discovery of 5\'end-dependent post-transcriptional activation of a *Bacillus subtilis* mRNA by the conserved regulatory sRNA RoxS. The authors propose that RoxS recognizes the *yflS* mRNA at the very 5\' end and thereby blocks 5\' exonucleolytic degradation of this target by RNase J1. This would be the first time a bacterial sRNA has been shown to regulate gene expression in trans by inhibiting 5\'-3\' exonucleolytic degradation, the latter of which being similar to RNA degradation in eukaryotes. In the second part of this manuscript, the authors present experiments indicating that RoxS binding also remodels structurally the *yflS* mRNA to make it more competent for translation. In the third part, RoxS is shown to be transcriptionally controlled by the important DNA binding protein Rex. Additionally, experiments are presented to elucidate RoxS activity under different nutritional conditions. Specifically, the authors show that RoxS expression is negatively regulated by Rex, a transcriptional repressor that is itself indirectly regulated by the presence of malate. A regulatory scheme for malate metabolism involving RoxS-mediated positive and negative regulation could be developed from these results ([Figure 11](#fig11){ref-type="fig"} is remarkable!).

Generally, the study is significant as much less is known about sRNA regulation in *B. subtilis* than in *E. coli*, and the *B. subtilis* suite of ribonucleases is considerably different from that of *E. coli* -- most notably the presence of a 5\' exoribonuclease (RNase J1), an activity that is not known to exist in *E. coli*. Furthermore, RoxS and regulatory sequences controlling its expression are conserved in other Gram-positives; thus, the current findings are likely broadly applicable.

The article is well written and the majority of the conclusions are well supported by the data. However, in its current form, the study lacks some key experiments and would benefit from a more thorough quantification of the data. For orientation, the first part of this manuscript, i.e. the discovery of sRNA-mediated mRNA activation by blocking 5\' exo decay, clearly constitute sufficient novelty to make this a strong candidate for an *eLife* paper. However, it needs to be better developed. The second part -- translational control -- is presently not convincing. The third part constitutes an important part, too, since it puts the activity of RoxS in physiological context.

Essential revisions:

1\) Subsection "Mapping of the 5' extremity of the *yflS* mRNA" and [Figure 2](#fig2){ref-type="fig"}: While primer extension is an effective technology to map the 5\' end of transcripts, it fails to determine the chemical nature of the 5\' end. In other words, the determined 5\' end might as well be that of a stable degradation intermediate. Differential 5\' RACE experiments (see PMID: 8755555) would be one way to test this hypothesis. Alternatively, there seem to be ample published RNA-seq data for Bacillus for the authors; do they support this transcription start site? In addition, is the promoter conserved? In any case, this part on 5\' end mapping seems rather confirmatory and doesn\'t deserve to be a main figure (move to the supplement).

2\) Subsections "RoxS regulates *yflS* mRNA stability" and "RoxS blocks degradation of the *yflS* mRNA by RNase J1": The control at the level of mRNA stability needs to be demonstrated more firmly. The authors should try to fully uncouple it from any translational control by using a non-translated 5\' fragment of the *yflS* mRNA. This can be achieved by co-expression of RoxS with such a shorter RNA, perhaps as a fusion with an unrelated stable transcript. This has been done with other sRNAs that activate targets by increasing mRNA stability (SgrS, PMID:23582330; RydC, PMID:24141880). Such shorter fusion RNA target would also aid better mutational studies of the target.

3\) Subsection "RoxS protects *yflS* mRNA from in vitro degradation by RNase J1": The prediction that C-rich regions of RoxS are involved in base pairing with the *yflS* mRNA comes out of the blue. Explain what\'s known about other RoxS-target interactions. Is the predicted target site in *yflS* mRNA supported by conservation at the nucleotide level?

4\) Subsection "RoxS protects yflS mRNA from in vitro degradation by RNase J1": Here and elsewhere, the predicted base pairing interaction remains to be more firmly demonstrated. Use compensatory base pair changes in sRNA and target, or show RNA structure probing data of both native and mutant variants of the RNA partners.

5\) Subsection "RoxS also activates translation of the *yflS* mRNA", second paragraph and [Figure 6](#fig6){ref-type="fig"}: It is puzzling that the CCR1+3 variant of RoxS still affords an almost two-fold translational activation (30S binding) of the target, especially in light of the fact that i) wild-type RoxS manages a mere 3-fold activation in this assay, and that ii) the CCR3 mutation should nullify base pairing (according to [Figure 1](#fig1){ref-type="fig"}). This again demands a better definition of the RoxS-*yflS* RNA interaction in order to design more suitable mutants. Moreover, the 30S toeprint assay should include a second non-target mRNA to demonstrate that RoxS activity is specific.

6\) Better quantification. [Figure 4](#fig4){ref-type="fig"}: It would be useful to quantify and plot the intensities of the bands corresponding to the 94 nt *yflS* transcript and the bands corresponding to AMP. [Figure 7](#fig7){ref-type="fig"}: the effect of RoxS on *yflS* in these experiments is approximately 2-fold, which probably presents the sum of transcript protection and translation activation. To discriminate the individual contributions of RoxS to this process, it would be useful to generate a *yflS* variant that is not translated (e.g. by mutating the start codon of the mRNA) and test the effect of RoxS on Northern Blots. [Figure 8](#fig8){ref-type="fig"}: Again, it would be useful to quantify the bands corresponding to RoxS in these experiments (e.g. by setting the 0 min time point to 100%). This would allow for a thorough comparison of RoxS expression across the presented experiments.

10.7554/eLife.23602.031

Author response

*Essential revisions:*

*1) Subsection "Mapping of the 5' extremity of the yflS mRNA" and [Figure 2](#fig2){ref-type="fig"}: While primer extension is an effective technology to map the 5\' end of transcripts, it fails to determine the chemical nature of the 5\' end. In other words, the determined 5\' end might as well be that of a stable degradation intermediate. Differential 5\' RACE experiments (see PMID: 8755555) would be one way to test this hypothesis. Alternatively, there seem to be ample published RNA-seq data for Bacillus for the authors; do they support this transcription start site? In addition, is the promoter conserved? In any case, this part on 5\' end mapping seems rather confirmatory and doesn\'t deserve to be a main figure (move to the supplement).*

To confirm that the mapped 5'end of *yflS* corresponds to a primary transcript, we performed a new reverse transcription reaction on total RNA treated (or not) with XRN1. This 5'-3' exoribonuclease digests RNA with a 5' monophosphate. We show that the mapped 5'end of *yflS* is resistant to digestion by XRN1, suggesting that this extremity is a 5' triphosphate, whereas a known processed transcript of the *hbs* mRNA is susceptible to XRN1 treatment. As suggested, we moved this figure to the supplemental information section ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

*2) Subsections "RoxS regulates yflS mRNA stability" and "RoxS blocks degradation of the yflS mRNA by RNase J1": The control at the level of mRNA stability needs to be demonstrated more firmly. The authors should try to fully uncouple it from any translational control by using a non-translated 5\' fragment of the yflS mRNA. This can be achieved by co-expression of RoxS with such a shorter RNA, perhaps as a fusion with an unrelated stable transcript. This has been done with other sRNAs that activate targets by increasing mRNA stability (SgrS, PMID:23582330; RydC, PMID:24141880). Such shorter fusion RNA target would also aid better mutational studies of the target.*

To uncouple mRNA stability from translational control of *yflS*, we constructed a strain in which the chromosomal copy of the yflS gene contained both a mutant SD sequence and a premature stop codon at the fifth codon (belt and braces approach!).The half-life of this *yflS^mutTR^*mRNA is a little shorter than the WT *yflS* mRNA (1.6 min vs. 2.5 min respectively; [Figure 8](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), as one might expect since translating ribosomes can no longer protect this mRNA from RNase Y. However, the *yflS^mutTR^* mRNA is still destabilized in absence of RoxS similar to the parental strains ([Figure 8B](#fig8){ref-type="fig"}). This result nicely confirms that RoxS can stabilise the *yflS* mRNA independently of its effect on translation.

*3) Subsection "RoxS protects yflS mRNA from* in vitro *degradation by RNase J1": The prediction that C-rich regions of RoxS are involved in base pairing with the yflS mRNA comes out of the blue. Explain what\'s known about other RoxS-target interactions.*

In a previous study, we showed that the C-rich region CRR3 of RoxS was involved in the interaction with the *ppnkB* mRNA target. We have better explained the rationale for focussing on the C-rich elements in the text (subsection "RoxS uses C-rich region 3 (CRR3) to interact with the extreme 5'-end of *yflS* mRNA", first paragraph).

*Is the predicted target site in yflS mRNA supported by conservation at the nucleotide level?*

*Bacillus subtilis* and related bacteria have several di- and tri-carboxylate transporters homologous to YflS making it difficult to identify this particular transporter with certainty. For those examples where we can be relatively sure, because synteny is maintained, the 5\'-UTR of *yflS* is highly conserved at the nucleotide level and, since the RoxS sRNA is identical to that of *B. subtilis* in these organisms, the potential base-pairing with CRR3 of RoxS is maintained. A figure showing an alignment of these 5\'-UTRs and the complementary section of RoxS is shown in the supplementary section ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) and a statement describing this conservation is included in the manuscript (subsection "Mapping of the 5' extremity of the *yflS* mRNA")

*4) Subsection "RoxS protects yflS mRNA from in vitro degradation by RNase J1": Here and elsewhere, the predicted base pairing interaction remains to be more firmly demonstrated. Use compensatory base pair changes in sRNA and target, or show RNA structure probing data of both native and mutant variants of the RNA partners.*

To confirm the base pairing prediction, we added 2 experiments to the paper.

In the first, we assayed the in vitro ability of RNase J1 to degrade mutant 5\' fragments of the *yflS* mRNA (*yflS^mut5\'^*), in which the predicted base-pairing with RoxS was disrupted and then restored with compensatory mutations in CRR3 (CRR3-2). In in vitro RNA degradation assays similar to those shown in [Figure 3](#fig3){ref-type="fig"}, we show that mutant RoxS (CRR3-2) shows weaker protection of wt *yflS* transcripts from RNase J1. Similarly, wt RoxS shows weaker protection of *yflS^mut5\'^*, whereas when the RNAs bearing compensatory mutations are mixed (CRR3-2 and *yflS^mut5\'^*), protection from RNase J1 degradation is recovered. This result confirms that the RoxS CRR3 element is involved in binding to the 5'-end of the *yflS* RNA. These data are included in a new figure ([Figure 4](#fig4){ref-type="fig"}).

We also probed the RoxS RNA secondary structure with RNase V1 and RNase T2 after addition of increasing concentrations of *yflS* RNA (Figure 3---figure supplement 1). This experiment showed increased cleavages by RNase V1 near CRR3 and increased protection from RNase T2 between CRR2 and CRR3 of RoxS upon addition of *yflS*, but no protection at the CRR1 sequence.

Together, these experiments demonstrate convincingly that RoxS uses the CRR2-3 region as predicted to interact with the *yflS* mRNA.

*5) Subsection "RoxS also activates translation of the yflS mRNA", second paragraph and [Figure 6](#fig6){ref-type="fig"}: It is puzzling that the CCR1+3 variant of RoxS still affords an almost two-fold translational activation (30S binding) of the target, especially in light of the fact that i) wild-type RoxS manages a mere 3-fold activation in this assay, and that ii) the CCR3 mutation should nullify base pairing (according to [Figure 1](#fig1){ref-type="fig"}). This again demands a better definition of the RoxS-yflS RNA interaction in order to design more suitable mutants.*

We have done the toeprint experiment three times and the quantification represents the average and error bars for these three experiments. Visually the result is always the same: the wt and the CRR1 mutant give a much stronger toeprint than either the CRR3 or CRR1+3 mutant and the apparent residual effect of these mutants, particularly CRR1+3, compared to the (-)RoxS control appears stronger in the quantification than to the eye. Furthermore, the U35 RT stop which is lost upon efficient RoxS binding to *yflS* (even in the absence of ribosomes e.g. lane 3) behaves as expected for the CRR3 or CRR1+3 mutants. We are confident that we have identified the correct base-pairing, particularly with the additional experiments provided (compensatory mutations, structure probing of RoxS). It is possible that since the base pairing extends into the CRR2 region (validated by RNase T2 structure probing of RoxS described above) that this is sufficient to account for the residual toe-print stimulation in vitro (it is unlikely to be sufficient in vivo in a more competitive environment). We have included a sentence stating that \"it is possible that the apparent residual effect of these mutants comes from the extended base-pairing around CRR2 in these in vitro experiments.\"

*Moreover, the 30S toeprint assay should include a second non-target mRNA to demonstrate that RoxS activity is specific.*

RoxS specificity was demonstrated in a previous paper. In Durand et al. *2015* ([Figure 11](#fig11){ref-type="fig"}),the toeprint experiment on the *sucC* mRNA shows that the full length of RoxS has strictly no impact on translation initiation of this mRNA.

*6) Better quantification. [Figure 4](#fig4){ref-type="fig"}: It would be useful to quantify and plot the intensities of the bands corresponding to the 94 nt yflS transcript and the bands corresponding to AMP.*

We have calculated the percent of AMP released compared to total signal (AMP + full-length transcript) and these graphs have been added to the Figure (now [Figure 3](#fig3){ref-type="fig"}).

*[Figure 7](#fig7){ref-type="fig"}: the effect of RoxS on yflS in these experiments is approximately 2-fold, which probably presents the sum of transcript protection and translation activation. To discriminate the individual contributions of RoxS to this process, it would be useful to generate a yflS variant that is not translated (e.g. by mutating the start codon of the mRNA) and test the effect of RoxS on Northern Blots.*

This has been done (also to address point no. 2) and has been included as a new [Figure 8](#fig8){ref-type="fig"}). It confirms that we can uncouple the two events.

*[Figure 8](#fig8){ref-type="fig"}: Again, it would be useful to quantify the bands corresponding to RoxS in these experiments (e.g. by setting the 0 min time point to 100%). This would allow for a thorough comparison of RoxS expression across the presented experiments.*

This has been done and added to the figure (now [Figure 9](#fig9){ref-type="fig"}).
